血液与肿瘤组织RAS突变检测指导转移性结直肠癌抗EGFR治疗的一致性
该前瞻性-回顾性队列研究纳入146例转移性结直肠癌患者,比较血浆游离DNA与肿瘤组织RAS突变检测的一致性。血浆BEAMing检测与标准PCR的一致性为89.7%(Kappa 0.80),组织BEAMing与标准PCR一致性为90.9%(Kappa 0.83)。血浆RAS检测可识别对抗EGFR治疗有反应的人群,预测水平与组织检测相当。
要点
- 血浆ctDNA BEAMing检测RAS与标准PCR一致性89.7%(Kappa 0.80)。
- 组织BEAMing检测RAS与标准PCR一致性90.9%(Kappa 0.83)。
- 15例(10.3%)组织-血浆结果不一致,48%患者血浆突变等位基因分数低于1%。
核心结论
- 血浆RAS检测总体一致性高,可识别对抗EGFR治疗有反应的人群,预测水平与标准组织检测相当。
研究设计与样本
- 前瞻性-回顾性队列研究,纳入146例转移性结直肠癌患者,肿瘤组织采用标准PCR技术检测RAS状态,血浆和组织均采用Digital PCR(BEAMing)检测。
主要发现
- 血浆BEAMing RAS检测与标准PCR一致性89.7%(Kappa指数0.80;95% CI 0.71-0.90)。
- 组织BEAMing与标准PCR一致性90.9%(Kappa指数0.83;95% CI 0.74-0.92)。
- 15例(10.3%)组织-血浆结果不一致;ctDNA分析发现9例组织未检出的低频RAS突变,可能因技术敏感性或异质性。
- 6例血浆未检出RAS突变,可能因肿瘤负荷低或ctDNA释放少。
- 接受抗EGFR联合伊立替康二线或三线治疗的患者,标准PCR与ctDNA检测预测治疗获益等效。
临床怎么用
- 血浆RAS检测的可行性和实用性可能使其成为抗EGFR治疗选择的替代工具。
局限性
- 15例(10.3%)组织-血浆结果不一致;9例低频RAS突变组织未检出,可能因技术敏感性或异质性。
- 6例血浆未检出RAS突变,可能因肿瘤负荷低或ctDNA释放少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Circulating tumor DNA (ctDNA) is a potential source for tumor genome analysis. We explored the concordance between the mutational status of RAS in tumor tissue and ctDNA in metastatic colorectal cancer (mCRC) patients to establish eligibility for anti-epidermal growth factor receptor (EGFR) therapy. PATIENTS AND METHODS: A prospective-retrospective cohort study was carried out. Tumor tissue from 146 mCRC patients was tested for RAS status with standard of care (SoC) PCR techniques, and Digital PCR (BEAMing) was used both in plasma and tumor tissue. RESULTS: ctDNA BEAMing RAS testing showed 89.7% agreement with SoC (Kappa index 0.80; 95% CI 0.71 - 0.90) and BEAMing in tissue showed 90.9% agreement with SoC (Kappa index 0.83; 95% CI 0.74 - 0.92). Fifteen cases (10.3%) showed discordant tissue-plasma results. ctDNA analysis identified nine cases of low frequency RAS mutations that were not detected in tissue, possibly due to technical sensitivity or heterogeneity. In six cases, RAS mutations were not detected in plasma, potentially explained by low tumor burden or ctDNA shedding. Prediction of treatment benefit in patients receiving anti-EGFR plus irinotecan in second- or third-line was equivalent if tested with SoC PCR and ctDNA. Forty-eight percent of the patients showed mutant allele fractions in plasma below 1%. CONCLUSIONS: Plasma RAS determination showed high overall agreement and captured a mCRC population responsive to anti-EGFR therapy with the same predictive level as SoC tissue testing. The feasibility and practicality of ctDNA analysis may translate into an alternative tool for anti-EGFR treatment selection.
引用
- Grasselli J, Elez E, Caratù G, et al. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol. 2017. PMID: 28368441. doi:10.1093/annonc/mdx112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。